{"title":"ASIA syndrome (autoimmune/inflammatory syndrome induced by adjuvants): Narrative literature review","authors":"Fabio Andrés Torres-Saavedra , Lina Paola León-Sierra , Julián Rondón-Carvajal","doi":"10.1016/j.rcreue.2024.07.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Adjuvant-induced autoimmune/inflammatory syndrome (ASIA) comprises a spectrum of clinical manifestations associated with exposure to diverse adjuvants that have in common the generation of non-specific autoantibodies and loss of immune tolerance.</p></div><div><h3>Objective</h3><p>This study aimed to develop a narrative review of the literature about the pathogenesis underlying ASIA syndrome, its differentiation from other defined autoimmune diseases, and prospects for future research in this field.</p></div><div><h3>Materials and methods</h3><p>A narrative review of the literature was conducted using Pubmed, Embase, and LILACS. All publications on the subject were included, with no time limit in English and Spanish. Finally, 25 articles published since 1990 were included, from which we reviewed the pathogenesis, diagnostic criteria, and its differentiation from other defined autoimmune processes.</p></div><div><h3>Results</h3><p>The appearance of ASIA syndrome seems to be linked to an individual’s genetic predisposition (HLA-DRB1*01 or HLA-DRB4) and is the result of the interaction of external and endogenous factors that trigger autoimmune phenomena. In recent years, physicians have become more aware of the relationship between exposure to adjuvants and the development of underlying signs and symptoms that may correspond to ASIA syndrome. The current evidence supporting its existence is still contradictory. A timely diagnosis requires a multidisciplinary approach and could require immunosuppressive treatment in particular cases.</p></div><div><h3>Conclusions</h3><p>In recent years a relationship between exposure to adjuvants and the appearance of autoimmunity phenomena has been recognized. In clinical practice, physicians can find cases of ASIA syndrome. However, the evidence is still debated on the relationship between adjuvants and autoimmune clinical manifestations. ASIA syndrome classification criteria require validation in various populations before being applied to select patients for clinical studies. It is necessary to identify the risk factors for ASIA syndrome to understand its pathophysiology and make a timely diagnosis.</p></div>","PeriodicalId":101099,"journal":{"name":"Revista Colombiana de Reumatología (English Edition)","volume":"31 3","pages":"Pages 380-389"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Reumatología (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2444440524000967","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Adjuvant-induced autoimmune/inflammatory syndrome (ASIA) comprises a spectrum of clinical manifestations associated with exposure to diverse adjuvants that have in common the generation of non-specific autoantibodies and loss of immune tolerance.
Objective
This study aimed to develop a narrative review of the literature about the pathogenesis underlying ASIA syndrome, its differentiation from other defined autoimmune diseases, and prospects for future research in this field.
Materials and methods
A narrative review of the literature was conducted using Pubmed, Embase, and LILACS. All publications on the subject were included, with no time limit in English and Spanish. Finally, 25 articles published since 1990 were included, from which we reviewed the pathogenesis, diagnostic criteria, and its differentiation from other defined autoimmune processes.
Results
The appearance of ASIA syndrome seems to be linked to an individual’s genetic predisposition (HLA-DRB1*01 or HLA-DRB4) and is the result of the interaction of external and endogenous factors that trigger autoimmune phenomena. In recent years, physicians have become more aware of the relationship between exposure to adjuvants and the development of underlying signs and symptoms that may correspond to ASIA syndrome. The current evidence supporting its existence is still contradictory. A timely diagnosis requires a multidisciplinary approach and could require immunosuppressive treatment in particular cases.
Conclusions
In recent years a relationship between exposure to adjuvants and the appearance of autoimmunity phenomena has been recognized. In clinical practice, physicians can find cases of ASIA syndrome. However, the evidence is still debated on the relationship between adjuvants and autoimmune clinical manifestations. ASIA syndrome classification criteria require validation in various populations before being applied to select patients for clinical studies. It is necessary to identify the risk factors for ASIA syndrome to understand its pathophysiology and make a timely diagnosis.
导言佐剂诱导的自身免疫/炎症综合征(ASIA)包括一系列与暴露于不同佐剂相关的临床表现,其共同点是产生非特异性自身抗体和丧失免疫耐受。所有与该主题相关的英文和西班牙文出版物均被收录,且无时间限制。结果ASIA综合征的出现似乎与个人的遗传倾向(HLA-DRB1*01或HLA-DRB4)有关,是引发自身免疫现象的外部和内源性因素相互作用的结果。近年来,医生们越来越意识到接触佐剂与出现可能与 ASIA 综合征相对应的潜在体征和症状之间的关系。目前支持其存在的证据仍然相互矛盾。结论 近年来,人们已经认识到接触佐剂与出现自身免疫现象之间的关系。在临床实践中,医生可以发现 ASIA 综合征的病例。然而,关于佐剂与自身免疫临床表现之间关系的证据仍存在争议。ASIA 综合征的分类标准需要在不同人群中进行验证,然后才能用于选择患者进行临床研究。有必要确定 ASIA 综合征的危险因素,以了解其病理生理学并及时做出诊断。